

Home Page

Executive Compensation

Introduction

We invite our stockholders to fill out a survey to provide input and feedback to the Compensation and Management Development Committee, or Compensation Committee, regarding our executive compensation policies and practices. All input from our stockholders is valuable and the Compensation Committee appreciates your time and effort in completing the survey.

Are you a stockholder? (Check one)

Yes

No

Name:

Are you a stockholder of record (i.e., do you hold shares directly in your name) or are you a "street name" holder (i.e., are your shares held in a stock brokerage account or by a bank, trust or other nominee)? (Check one)

I am a stockholder of record.

My shares are held in street name.

Are you an individual investor or representing shares owned on a company's behalf? (Check one)

I am an individual investor.

The shares are owned in a company or other entity's name and I am answering these questions on the company or other entity's behalf.

Company:

I represent that I own

shares of Amgen Inc. stock.

Are you interested in taking this ten question compensation practices survey or are you comfortable that Amgen's executive compensation practices are appropriate? (Check one)

I would like to take the survey.

© 2009 Amgen Inc. All Rights Reserved.



Home Page

Executive Compensation

Executive Compensation Survey

The following survey questions are provided by TIAA-CREF¹. After each TIAA-CREF question, we have linked to information that you may find helpful in preparing your answer.

10 TIAA-CREF QUESTIONS FOR THE EVALUATION OF CD&A'S*

1. Is the compensation plan performance-based?

Amgen believes our compensation programs are performance based (click here to learn more)

2. Is the plan clearly linked to the company's business strategy? Does the CD&A support the MD&A?

Amgen believes our plans and programs are clearly linked to our business strategy and our CD&A supports our MD&A (click here to learn more)

3. Are the plan's metrics, goals and hurdles clearly and specifically disclosed? Are they understandable? Do they make sense?

Amgen believes our compensation plans and programs metrics, goals and hurdles are clearly and specifically disclosed (click here to learn more)

4. Are the incentives clearly designed to meet the company's specific business challenges, both short and long-term?

Amgen believes that our incentives are clearly designed to meet our specific short and
long-term business challenges (click here to learn more)

5. Is the plan customized to suit the company's size, industry, performance, competitive position?

Amgen believes that our compensation plans and programs are customized to suite our size, industry, performance and competitive position (**click here to learn more**)

6. Does the compensation of senior executives complement the company's overall compensation program so as to reinforce internal equity and promote the success of the entire business enterprise?

Amgen believes that the compensation of our senior executives complement our overall compensation program so as to reinforce internal equity and promote the success of the entire business enterprise (click here to learn more)

7. Does the plan avoid abuses and comply with the best practices outlined in our Policy Statement?

Amgen believes that our plans and programs avoid abuses and comply with best practices outlined TIAA-CREF's Policy Statement (click here to learn more)

8. Does the plan promote long-term value creation, which is the primary objective of shareholders?

Amgen believes that our plans and programs promote long-term value creation (click here to learn more)

9. Does the plan articulate a coherent compensation philosophy appropriate to the company and clearly understood by directors?

Amgen believes that our plans and programs articulate a coherent compensation philosophy appropriate to our Company and clearly understood by our directors (click here to learn more)

10. Are we convinced?

Amgen hopes that you are convinced (click here to learn more)

@ 2009 Amgen Inc. All Rights Reserved.

¹Amgen is not affiliated with TIAA-CREF. Any link from this website to an external website does not imply a recommendation or endorsement of the website or the views expressed thereon. We have no control over the nature, content and availability of those sites. Amgen does not give any representation regarding the quality, safety, suitability, or reliability of any external websites or any of the content or materials contained in them.

^{*} These questions should be read in the context of the TIAA-CREF Policy Statement on Corporate Governance, available at http://www.tiaa-cref.org/pubs/pdf/governance_policy.pdf.